James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Why Are Marijuana Stocks Growing Like Weeds Right Now?

Marijuana-related stocks have doubled and even tripled in just a matter of days. The impetus is less than promising, even if the industry's future looks bright.

Kiss These 4 Stocks Goodbye if the Broader Market Tanks

The same stocks that investors have been cheering for months could be subject to the loudest boo-birds should the market start a significant pullback.

China’s Pollution Problem About to Become Everyone’s Problem

Temporary factory shutdowns and longer-term initiatives to fix China's pollution problem will ruffle the feathers of hundreds of American companies.

What Would Microsoft Want With Dell?

A Dell buyout could be announced as soon as today, and while the benefits are clear for DELL shareholders, what Microsoft might get out of this isn't so clear.

Instead of Bizarre Super Bowl Prop Bets …

If you're tempted by bets like how much time it will take Alicia Keys to finish the national anthem, these three high-risk/high-reward stocks might be for you.

4 Things About This Rally That Terrify Me

When things look too good to be true, odds are the rug is about to get pulled out from underneath us -- if only a little bit.

Keryx: An Important Biotech Reality Check in 5, 4, 3 …

This stock's tripling in the past month is your prototypical biotech "win." But if you don't lock in your gains now, you don't understand the game.

Funds Bitten by Apple Will Be Twice Shy

With its mighty tumble -- especially below the key $500 mark -- big fund and institutional holders won't be quick to buy again.

Forget Managed Funds — Pick Your Own Small-Cap Stocks

The edge that small-cap gurus used to enjoy has been deteriorating, so you're better off picking the stocks yourself instead of buying a managed fund.

Don’t Assume One Bellwether Stock Is as Good as Another

Is it possible that even a very basic assumption -- the link between major cyclical companies and the overall market -- doesn’t actually hold water?